|
| (i) Origins: sarcomatous versus carcinomatous monoclonal versus biclonal versus polyclonal. |
| (ii) Demographics: more common in Afro-American versus Caucasian women. |
| (iii) Aetiology: radiation inducible tumour versus metaplastic versus dedifferentiation versus common stem cell. |
| (iv) Pathogenesis: collision theory versus combination theory versus conversion theory. |
| (v) Risk factors: beneficial effect of oral contraceptives versus detrimental effect of exogenous estrogens. |
| (vi) Presentation: symptomatic (pyometra/vaginal bleeding/abdominal pain) versus asymptomatic. |
| (vii) Microscopic: biphasic components—separated versus merged. |
| (viii) MRI description: endophytic with architectural obliteration versus exophytic with no invasiveness. |
| (ix) Sonography: diagnostic use—yes versus no technique—transabdominal versus transvaginal. |
| (x) Surgery: lymphadenectomy versus nolymph-node dissection. |
| (xi) Adjuvant therapy: radiotherapy versus chemotherapy versus molecular targeted versus multimodality therapy. |
| (xii) Radiotherapy: locoregional control versus improved overall survival limited pelvic radiation versus whole abdominal radiation. |
| (xiii) Chemotherapy: single-agent versus combination versus targeted antineoplastic therapy. |
| (xiv) Prognostic features: ?significance of tumour size, patient age, and histology of sarcomatous element. |
|